HBIO
Harvard BioscienceBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-23
Current thesis
The constructive case is that Q1 2026 confirmed margin resilience, the refinancing removed the immediate going-concern overhang, and Project Viking can translate into better throughput and lower fixed costs if execution remains orderly.
Posture
Constructive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-07-30.
What can break
Capital structure risk: $40M of borrowings plus warrant overhang leaves dilution and refinancing sensitivity in place.
Momentum
94
Value
63
Sentiment
25
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.00 · Bull $7.25 · Bear $2.75
Earnings
2026-07-30
Data freshness
Prices
As of 2026-07-23
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-27 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-23
Investment thesis
As of 2026-07-23
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $6.00
Why
Momentum94 · Δ7d -
Value63 · Δ7d -0.5
Sentiment25 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
94
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
63
39% active weight
Current posture
7d trendFlat
Δ7d
-0.5
Δ21d
-0.4
Sentiment
25
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 93.7 / Value 63.3 / Sentiment 24.9
Fundamentals (TTM)As of 2026-07-22
Fundamentals (TTM)
As of 2026-07-22
Market Cap
$27.65M
Beta
1.55
Shares Out
4.51M
P/E (TTM) · Derived
-0.5
P/S (TTM)
0.35
P/FCF (TTM)
4.47
Rev YoY
-4.7%
EPS YoY
-93.3%
Gross Margin
+54.1%
Op Margin
-56.1%
Net Debt
$35.66M
Current Ratio
1.99
As of 2026-07-23 • Updated nightlySource: Internal modelMethodology